a profile shared with the parent molecule. In preclinical species, RP101075 and RP101442 produce robust, dose dependent lymphopenia. RP101075 (0.1 and 0.3mpk) and RP0101442 (0.4 and 0.8mpk) had therapeutic benefit in MOG35-55 peptide induced mouse EAE, achieving efficacy equivalent to RPC1063 and FTY720 (Gilenya™).
CureOrBust wrote:So it Gilenya by a different company? But, who knows, it may be slightly better than Gilenya in human trials.
Users browsing this forum: No registered users